Patents by Inventor Jeremy Besnard

Jeremy Besnard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250084090
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Application
    Filed: November 18, 2024
    Publication date: March 13, 2025
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Publication number: 20250051327
    Abstract: Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of MALT-1. Such compounds are represented by Formula (I) and Formula (II), wherein the variables are defined herein.
    Type: Application
    Filed: November 23, 2021
    Publication date: February 13, 2025
    Inventors: Peter Ray, David Evans, Anthony Bradley, Chris Radoux, Simon Richards, Catarina Santos, Jérémy Besnard, Andrew John Cooke, Sylvie Félicité Gomez, Lorène Nathalie Sabine Cazaux-Lerou, Marta Pinto, Sabrina Pucci, Claire Christiane Ginette Blanger
  • Patent number: 12180213
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 31, 2024
    Assignee: SUMITOMO PHARMA CO. LTD.
    Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Publication number: 20240400556
    Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: May 3, 2024
    Publication date: December 5, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Hasane Ratni, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20240262821
    Abstract: Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of PKC-theta. Such compounds are represented by Formula I, wherein the variables are defined herein.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 8, 2024
    Applicant: Exscientia Al Limited
    Inventors: Peter Ray, Anthony Bradley, Simon Richards, Catarina Santos, Jeremy Besnard, Jérôme Meneyrol, Virginie Suchaud
  • Publication number: 20240239794
    Abstract: Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of PKC-theta. Such compounds are represented by Formula I, wherein the variables are defined herein.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 18, 2024
    Applicant: Exscientia AI Limited
    Inventors: Peter Ray, Anthony Bradley, Simon Richards, Catarina Santos, Jeremy Besnard, Jérôme Meneyrol, Virginie Suchaud
  • Publication number: 20240132489
    Abstract: An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystal form or solvate of any one of the foregoing. The aromatic heterocyclic compound has a novel structure, good CDK7 inhibitory activity, and good selectivity.
    Type: Application
    Filed: August 27, 2021
    Publication date: April 25, 2024
    Inventors: Xiaohui GU, Haiyun BAI, Olivier Rémy BARBEAU, Jérémy BESNARD
  • Publication number: 20240124504
    Abstract: An aromatic heterocyclic compound, and a pharmaceutical composition and an application thereof. Specifically disclosed are a compound as represented by formula I-A, a stereoisomer thereof, a diastereoisomer thereof, or a pharmaceutically acceptable salt of any one of the described substances, or a crystalline form or a solvate of any one of the described substances. The aromatic heterocyclic compound is novel in structure, and has good CDK7 inhibitory activity and good selectivity.
    Type: Application
    Filed: August 27, 2021
    Publication date: April 18, 2024
    Inventors: Xiaohui GU, Haiyun BAI, Olivier Rémy BARBEAU, Jérémy BESNARD
  • Publication number: 20230399308
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 14, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Hiro UEMACHI, Tomomi OHNO, Jeremy BESNARD
  • Publication number: 20230382911
    Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: July 28, 2023
    Publication date: November 30, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon BELL, Jérémy BESNARD, Anthony Richard BRADLEY, Luke GREEN, Wolfgang HAAP, Buelent KOCER, Andreas KUGLSTATTER, Xavier LUCAS, Patrizio MATTEI, Dmitry MAZUNIN, Claus RIEMER, Willem Paul VAN HOORN
  • Patent number: 11780820
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: October 10, 2023
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Hiro Uemachi, Tomomi Ohno, Jeremy Besnard
  • Publication number: 20230227449
    Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Hasane Ratni, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20230219953
    Abstract: The present invention provides compounds of formula I wherein X1, X2, X3, X4, R1, R1a, R1b, R2?, R2?, R3?, R3?, R6 and R7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 13, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20230008875
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Application
    Filed: August 17, 2022
    Publication date: January 12, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Patent number: 11466007
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: October 11, 2022
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Publication number: 20220213079
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 7, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Patent number: 11339151
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: May 24, 2022
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Yuki Fujii, Masayuki Sakuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Publication number: 20220073506
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Publication number: 20210332025
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Application
    Filed: April 23, 2021
    Publication date: October 28, 2021
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidefumi YOSHINAGA, Hiro UEMACHI, Tomomi OHNO, Jeremy BESNARD
  • Patent number: 11014905
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 25, 2021
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Hiro Uemachi, Tomomi Ohno, Jeremy Besnard